INTRODUCTION
In recent years, there has been a growing recognition of the capability of human FOXP3 + T regulatory (Treg) cells to suppress adverse immune responses.
Much research effort has been devoted to implementing Treg-cell therapy in the clinic (1, 2) and the first clinical trials have been recently reported (3, 4) . Due to their reduced circulating frequency (i.e., 5-10% of the CD4 + T cells) FOXP3 + Treg cells, to be of any therapeutic use in cell-therapy trials, need to be expanded ex vivo.
The intrinsic reduced Treg-cell ability to proliferate in vitro can be reversed by potent stimulation through the TCR in the presence of high doses of exogenous IL-2 (5).
Protocols for the expansion of human FOXP3 + Treg cells performed under conditions of good manufacturing practice (GMP) have been shown to be feasible (3, (6) (7) (8) .
Importantly, these culture conditions are also highly advantageous for the expansion of effector CD25 + T cells, which may contaminate the starting peripheral FOXP3 + Treg cells. This obstacle can be bypassed by (i) the use of cord blood Treg cells (4),
(ii) isolation of highly pure peripheral Treg cells through flow-based cell sorters (3, 9, 10) or (iii) the addition of rapamycin to the culture, which preferentially inhibits proliferation of effector T cells while sparing Treg cells (11, 12) .
IL-17 is a proinflammatory cytokine with non redundant functions in the clearance of extracellular pathogens (reviewed in 13). In humans, IL-17 is associated with many inflammatory disorders such as rheumatoid arthritis, asthma, multiple sclerosis, Crohn's disease and allograft rejection (reviewed in 14) . The majority of IL-17 derives from a population of CD4 + T cells known as Th17 (13) . The combination of cytokines that stimulates the development and stabilizes human Th17 cells is a subject of much debate (reviewed in 15). It appears that TGF-β, IL-21, IL-23, IL-6, and IL-1β at various dosages and combinations, depending on the experimental conditions and the starting T-cell subset, are essential for Th17-cell generation/expansion (15) .
It has been recently shown that a memory fraction of CD25 high FOXP3 + T cells contain a significant number of IL-17 producing cells which lack regulatory activity (16, 17) . In the context of concerted efforts to use expanded population of Treg cells for adoptive therapy in human T-cell mediated diseases, the risk of Th17-cell contamination is a key, as transfer of contaminant pro-inflammatory cells may exacerbate rather than ameliorate disease. Thus, developing methods of securing ex vivo expanded Treg cells intended for clinical use and inhibiting their proinflammatory potential in vivo have become all-important aspects of Treg-cell mediated immunotherapy (18) .
We set up a clinical-applicable protocol for the expansion of human peripheral
Treg cells using rapamycin to set the basis for an investigator-initiated clinical trial.
Th17-cell content and the in vivo stability of the rapamycin-expanded human FOXP3 + Treg cells were investigated as critical pertinent aspects of cell-based therapy.
DESIGN AND METHODS

Blood samples
Peripheral blood was obtained from healthy donor buffy coats obtained upon written informed consent in accordance with the Declaration of Helsinki under the protocol approved by the San Raffaele Scientific Institute Ethics Committee (protocol TIGET PERIBLOOD).
Treg-cell purification
Peripheral blood mononuclear cells (PBMC) were separated by density-gradient centrifugation over Lymphoprep (Axis-shield, Oslo, Norway). A portion of PBMC were cryopreserved for later use. The remaining PBMC were processed by using the CD8 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. Treg cells were then isolated from the negative cell fractions (CD8 -cells) using the CD25 MicroBeads (Miltenyi Biotec) following the manufacturer's instructions.
Flow cytometry
The cells were stained for surface antigens with the following monoclonal antibodies 
Cell cultures
CD8
-CD25 + T cells isolated from PBMC of healthy subjects were plated at 0.1 x 10 6 /ml in X-vivo 15 medium (Lonza, Verviers, Belgium) supplemented with 5%
pooled AB human serum (Lonza) and 100 U/mL penicillin/ streptomycin (BristolMyers Squibb, Sermoneta, Italy) in the presence or absence of 100 nM rapamycin (i.e. 100 ng/ml) (Rapamune®, Whyet, Maidenhead, Berkshire) (12) . The cells were activated with GMP grade beads coated with anti-CD3 and anti-CD28 antibodies (T Cell Expander® from Dynal Biotech ASA, Oslo, Norway) at a 1:3 ratio (cell:bead). At day 2 post activation, IL-2 (500 U/ml) (Proleukin®, Chiron, Amsterdam, Netherlands) was added to the culture and replenished as shown in Figure 1 . Beads were removed at the end of 14 days of culture by magnetic adherence and the expanded cells were used for further analyses.
Vβ repertoire analysis
The starting and the 14-day cultured T cells were stained with CD4 PerCp (clone SK3, BD) and CD25 APC (clone 2A3, BD) mAbs and with TCR V-beta Repertoire Kit (Immunotech) according to the manufacture's instructions.
Suppression assay with T MED and T RPM cells
Previously frozen PBMC were thawed and stained with CFSE (Molecular Probes, Eugene, OR, USA) (11) and suppression assay was performed as previously described by our group (12 (12) .
Cytokine detection in T MED and T RPM cells
The 14-day cultured T cells were plated at 0.5x10 6 cells in 500µl in 48 well-plates and stimulated for 6 hours with latex-beads (Eugene, Oregon, USA) (pre-coated with anti-CD3 (OKT3 clone) and anti-CD28 (clone CD28.2, BD Pharmingen) mAbs at 500 ng and 50 ng for 10 6 beads, respectively at a 1:2 ratio (cell:bead) in the presence of 10 µg/ml Brefeldin A (Sigma-Aldrich). At the end of the 6-hour activation, a surface cell staining was performed with anti-CD4 PerCp mAb (clone SK3, BD).
Subsequently, the intracellular staining was performed with the following mAbs: anti- 
T H 17-cell differentiation/expansion
The T MED and T RPM cells were plated at 0.5x10 6 /ml and cultured with 5 ng/ml TGF-β (R&D System, Minneapolis, MN, USA), 25 ng/ml IL-21 (Cell sciences, Canton, MA, USA) and 25 ng/ml IL-23 (R&D System) as previously described (19 
Statistical analysis
All statistical analysis were performed using the Student t-test two tails and values at P<0.05 were deemed significant.
RESULTS
Human Treg cells were enriched from PBMC using GMP-grade available magnetic beads, which are the best alternative to clinical grade flow-based cell sorters (8) . We first depleted CD8 + T cells and then positively selected CD25 + cells.
The purified cell subset (termed CD25 + ) contained a median of 80±10% CD4 + CD25
+ cells and 61±5% of CD25 + FOXP3 + cells (data not shown). CD25 + cells were cultured ex vivo to obtain the best Treg-cell expansion in the shortest time possible.
Increasing doses of GMP-grade anti-CD3/CD28-coated beads (from 1:1 to 1:5 cell:bead) and IL-2 (from 100 to 1000 U/ml), and different lengths of culture (from 7 to 21 days) in the presence or absence of rapamycin (T RPM and T MED cells, respectively) were tested. The optimal expansion protocol was 14 days of culture in the presence of 3 beads per cell and 500 U/ml of exogenous IL-2 (scheme depicted in Figure 1A ).
T RPM cells expanded 1 log less than T MED cells with a 7-day time-lag ( Figure   1B ), as we previously observed upon expansion of un-fractionated human CD4 + T cells (12) . T RPM cells contained an average of 51% FOXP3-expressing cells (range:
32-80%). Helios, a member of the Ikaros transcription factor family, is thought to be a specific marker of thymic-derived Treg cells (22) . We found an average of 73% We previously showed that rapamycin can be considered as a "selective Treg cell growth-survival" since it inhibits proliferation of non-Treg cells (12) which follow different molecular signalling pathways than Treg cells (24, 25) . Analysis of the cytokine production profile of T MED and T RPM cells confirmed that the presence of rapamycin in the culture reduces the frequency of T cells releasing pro-inflammatory cytokines ( Figure 3 ).
Recent findings demonstrate that FOXP3 + T cells contain some IL-17-producing non-Treg-cells (16, 17) and that naïve FOXP3 + Treg cells can differentiate into Th17 cells in the presence of IL-2 and lineage-specific polarizing factors (26) . As a consequence, we wondered whether the CD25 + T-cell starting population contained significant numbers of Th17-cells or Th17-cell precursors, recently found to be highly enriched within the CCR6 + CD161 + cell fraction (27, 28) , which might expand upon the 14-day culture. The starting CD25 + T-cell subset was slightly enriched in CCR6 + CD161 + T cells, as compared to the un-fractionated PBMC ( Figure   4A ). Thus, we tested the IL-17-producing cell content in T MED and T RPM cells. Low We previously reported that rapamycin permits the preferential enrichment and subsequent expansion of mouse (11) We found that expanded Treg cells have a reduced in vivo proliferative capacity as compared to the same number of freshly isolated T cells, confirming data from the past performed with total T cells (29) . However, the transferred T cells do survive for as long as 19 days after in vivo transfer (latest time point analysed) and despite being exposed to the critical TBI-induced cytokine storm they remain stable in their phenotype and in their suppressive activity.
It is evident that many issues need to be solved prior to using ex vivo 
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